TB-500 vs KPV
Both are repair-adjacent peptides sold together in our KLOW Blend, but they act on different parts of the repair process entirely — one on the cytoskeleton that lets cells move, the other on the inflammatory signaling that surrounds an injury.
At a Glance
| TB-500 | KPV | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Molecular class | Synthetic fragment of thymosin beta-4 (a 43-amino-acid parent molecule) | Tripeptide (3 amino acids), the minimal active fragment of alpha-MSH(11-13) |
| Discovery timeline | 1981 (parent molecule), actin-binding activity characterized in the early 1990s | Characterized by Anna Catania and James Lipton's research group at Weill Cornell |
| Primary mechanism studied | Actin regulation, cell migration | Anti-inflammatory activity, independent of the melanocortin receptor's pigmentation effects |
| Common research focus | Tissue repair, regeneration, and wound-healing models | Cytokine signaling and gut-inflammation models |
| Human clinical trial data | None for TB-500 itself — a distinct molecule from full-length Thymosin Beta-4's RegeneRx trials | None completed — evidence limited to animal and in-vitro research |
| Sold as a blend | Yes — see KLOW Blend and TB-500 + BPC-157 Blend | Yes — see KLOW Blend |
How They Differ
TB-500's research lineage traces to thymosin beta-4, a molecule first studied as part of the immune system before researchers discovered its real significance was as a G-actin-sequestering protein — meaning it directly regulates the cell's cytoskeleton. That mechanism gives TB-500 a structural role in repair research: it's studied for how it helps cells physically migrate into a wound or injury site. See its full discovery history, or how it compares to BPC-157.
KPV's lineage is different: it's the minimal active fragment of alpha-MSH, a hormone best known for its role in pigmentation. Researchers found that KPV retains alpha-MSH's anti-inflammatory activity while showing no pigmentation effect, which redirected its research focus toward cytokine signaling and gut-inflammation models specifically — a signaling role rather than a structural one. See its full discovery history, or how it compares to GHK-Cu and BPC-157.
Why They're Often Studied Together
Because TB-500's cytoskeletal/cell-migration mechanism and KPV's anti-inflammatory cytokine modulation act on different, complementary parts of the repair process — getting cells to the injury site versus controlling the inflammatory response around it — researchers studying regenerative pathways together often reference both compounds. That's the same rationale behind combining them, alongside BPC-157 and GHK-Cu, in the KLOW Blend.
TB-500 vs KPV questions
Are TB-500 and KPV studied for the same thing?
Not exactly. TB-500's research base centers on actin regulation and cell migration — a structural, cytoskeletal mechanism relevant to how repair cells move into an injury site. KPV's research base centers on anti-inflammatory activity tied to cytokine signaling, with a particular focus on gut-inflammation models. Both are combined in the KLOW Blend as complementary parts of the repair process.
Have TB-500 and KPV completed human clinical trials?
No, not as sold for research use. TB-500 as sold is a distinct molecule from the full-length Thymosin Beta-4 that RegeneRx Biopharmaceuticals tested in human trials — that clinical data does not directly apply to TB-500 itself. KPV has no completed human trials, with evidence limited to animal and in-vitro research.
Does this comparison mean TB-500 and KPV are approved for a particular use?
No. This page compares TB-500 and KPV for educational and research context only. Both are sold strictly for laboratory research use and are not evaluated or approved for human or animal use.
Looking for specs and pricing?
View purity, available sizes, and pricing for both.